Biogen acquires Cirara (intravenous glyburide) from Remedy Pharma , a drug which is intended to treat large hemispheric infarction (LHI). Biogen

Biogen announced that it has completed an asset purchase of Remedy Pharmaceuticals� Phase III candidate, Cirara (intravenous glyburide). The target indication for Cirara is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The FDA recently granted Cirara Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted Cirara Fast Track designation.

Biogen plans to continue the development and commercialization of Cirara. Under the terms of the agreement, Remedy will share in the cost of development for the target indication for Cirara in LHI stroke. Biogen will make an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties.